KE

Kimball Electronics, Inc. (KE) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended December 31, 2025 (Fiscal Q2 2026). Kimball Electronics, Inc. is a global provider of electronics manufacturing services (EMS) and contract manufacturing organization (CMO) solutions serving automotive, medical, and industrial markets. The company operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 5% in Q2 and 3% year-to-date compared to the prior year. The automotive vertical saw a 13% decline in Q2 due to the loss of a major program and tariff-related demand pressure. Conversely, the medical vertical grew 15% in Q2 driven by a key customer and new program wins.
• Margin Expansion: Gross margin improved significantly to 8.2% in Q2 (from 6.6% prior year) and 8.0% YTD (from 6.4% prior year). This was driven by restructuring efficiencies, the closure of the Tampa facility, and favorable foreign exchange rates.
• Expense Management: Restructuring expenses decreased to $1.8 million in Q2 (from $4.7 million prior year) as the Tampa closure plan neared completion. However, Selling and Administrative (S&A) expenses increased 41% in Q2 due to higher wages, benefits, and profit-sharing bonuses linked to improved performance.
• Profitability: Operating income increased 31% in Q2 and 45% YTD. Net income for the six months ended Dec 31, 2025, more than doubled to $13.7 million compared to $6.6 million in the prior year period.

Outlook, Risks, and Management Commentary

• Restructuring & Tampa Closure: The Tampa facility closure is substantially complete. Assets held for sale ($6.6 million) are expected to be disposed of in fiscal 2026, with proceeds anticipated to exceed carrying value and restructuring costs. Management expects to incur additional restructuring costs as necessary to align with demand and tariff environments.
• Tariffs and Geopolitics: The company is monitoring evolving global tariffs and geopolitical risks. While they expect to pass tariff costs to customers, failure to do so could adversely impact results.
• Liquidity: The company maintains a strong balance sheet with a current ratio of 2.2 and debt-to-equity of 0.3. Total available liquidity (cash + unused credit facilities) is approximately $363 million. Management expects sufficient liquidity to fund operations and capital expenditures for the next 12 months.
• Capital Allocation: The company continues to repurchase common stock under a $120 million plan, having repurchased $5.8 million in the first six months of fiscal 2026. Capital expenditures of $28.7 million YTD were primarily for a new medical facility in Indianapolis and capacity expansions.
• Tax Reform: The "One Big Beautiful Bill Act" enacted in July 2025 resulted in a partial release of the valuation allowance against business interest limitation deferred tax assets.

Investor Verification Checklist

• Automotive Exposure: Verify the extent of the "major automotive program" loss and the specific impact of tariffs on North American demand.
• Tampa Asset Sale: Monitor the timeline and actual proceeds from the sale of the Tampa facility assets classified as "Held for Sale."
• Medical Growth Sustainability: Assess the durability of the 15% growth in the medical vertical and the concentration risk associated with the largest medical customer.
• Working Capital Efficiency: Review the Cash Conversion Days (CCD) trend, which improved to 91 days in Q2 from 107 days in the prior year, to ensure continued efficiency in managing receivables and inventory.
• Debt Covenants: Confirm continued compliance with the primary credit facility covenants (leverage ratio < 3.0x and interest coverage > 3.5x) amidst fluctuating EBITDA.